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Abstract
Background and Aims: Gaucher disease (GD) is associated with peculiar metabolic 
abnormalities (ie hypermetabolic state, peripheral insulin resistance, dyslipidaemia), 
partially reverted by enzyme replacement therapy (ERT) at the expense of weight 
gain. Such metabolic alterations together with an unhealthy lifestyle acquired by an 
ageing GD population may favour the development of liver steatosis. We aimed at 
evaluating the prevalence of significant liver steatosis and at identifying the factors 
associated with liver steatosis in a cohort of patients with type 1 GD.
Methods: Twenty adult type 1 GD patients from an Italian academic referral cen-
tre were prospectively submitted to vibration-controlled transient elastography 
(Fibroscan®) with controlled attenuation parameter (CAP); significant steatosis was 
defined as CAP values ≥250 dB/min.
Results: Median CAP values were 234 [165-358] dB/min and 8 patients (40%) had 
significant steatosis. Significant steatosis was associated with indices of adiposity 
(weight, BMI and waist circumference), high blood pressure, insulin resistance and 
metabolic syndrome. GD-related variables and dose and duration of ERT were not 
associated with significant steatosis. In the subgroup of 16 patients on stable ERT 
for at least 24 months, CAP resulted significantly and positively associated with liver 
stiffness (rho 0.559, P = .024).
Conclusions: Significant steatosis is highly prevalent in adult type 1 GD patients and 
is strongly associated with a worse metabolic profile, featuring metabolic dysfunc-
tion-associated fatty liver disease (MAFLD). MAFLD may determine liver fibrosis 
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1  | BACKGROUND
Gaucher disease (GD) is a lysosomal storage disorder caused by bi-
allelic loss-of-function mutations in the glucocerebrosidase (GBA1) 
gene leading to glycosphingolipid accumulation in cells of the reticulo-
endothelial system.1,2 Hepatosplenomegaly, thrombocytopenia and 
bone disease are the major presenting features of type 1 GD, the most 
frequent chronic visceral variant.3,4 Liver involvement in type 1 GD 
is almost universal and ranges from hepatomegaly, with or without 
liver enzymes alterations, to liver fibrosis, cirrhosis, portal hyperten-
sion and hepatocellular carcinoma.2,5-7 GD is also characterized by 
peculiar metabolic abnormalities, including hypermetabolic state, pe-
ripheral insulin resistance and dyslipidaemia with low plasma levels 
of high-density lipoprotein (HDL) cholesterol,8-11 owing to lysosomal 
dysfunction, alterations in sphingomyelin-ceramide-glycosphingolipid 
pathways and systemic chronic low-grade inflammation.12,13 These 
same pathophysiological mechanisms have been increasingly recog-
nized in the pathogenesis of some common acquired conditions, such 
as obesity and metabolic syndrome (MetS).12,13 Enzyme replacement 
therapy (ERT), very effective on visceral, haematological and skeletal 
complications of GD, has significantly improved expectancy and qual-
ity of life of type 1 GD patients,14 but a significant weight gain has been 
reported in several patients with time.8,15 Moreover, as for the general 
population, ageing GD patients are increasingly exposed to unhealthy 
lifestyle, such as caloric intake excess, unbalanced diet, excessive al-
cohol consumption and sedentariness.8 Owing to this background, it 
could be expected that the prevalence of liver steatosis in adult type 1 
GD patients is remarkable.
Liver steatosis is characterized by the ectopic storage of tri-
glycerides in hepatocytes, and is mainly related to the components 
of the MetS, featuring metabolic dysfunction-associated fatty 
liver disease (MAFLD), formerly named non-alcoholic fatty liver 
disease (NAFLD).16-18 MAFLD is determined by an unbalance be-
tween the rate of hepatic triglycerides synthesis and catabolism as 
a result of an altered whole-body energetic homeostasis resulting 
from caloric intake exceeding caloric expenditure.19 Paralleling the 
worldwide increase in obesity, diabetes and metabolic risk abnor-
malities, MAFLD is the most rapidly growing cause of chronic liver 
disease,20,21 and is strongly associated with the risk of liver fibro-
sis/cirrhosis, end-stage liver disease and hepatocellular carcinoma 
(HCC), leading to increased liver-related morbidity and mortality.22 
Of note, MAFLD acts synergistically with concurrent chronic liver 
disease to further accelerate the progression of liver injury.23-26 
As a consequence, it could be hypothesized that GD patients 
with liver steatosis are at higher risk of developing advanced liver 
disease.
Controlled attenuation parameter (CAP) is a recently developed 
non-invasive tool for qualitative and quantitative assessment of liver 
steatosis.27 CAP measures the degree of ultrasound attenuation as a 
result of hepatic fat based on signals acquired by a technology named 
vibration-controlled transient elastography (VCTE) implemented on 
Fibroscan®.28 Several studies have clearly shown that CAP values 
are strongly associated with obesity, MetS and alcohol consump-
tion, variables epidemiologically associated with liver steatosis.29,30 
Moreover, large prospective studies including patients with chronic 
liver diseases of various aetiologies consistently reported a good 
correlation of CAP values with the amount of steatosis assessed by 
liver biopsy.31-34 Of note, since CAP is integrated in Fibroscan®, it is 
possible to have a one-shot reliable non-invasive assessment of both 
liver steatosis and fibrosis using the same equipment.
In this prospective study, we aimed to assess the prevalence of 
significant liver steatosis and to identify the factors associated with 
liver steatosis evaluated by VCTE with CAP in adult patients with 
type 1 GD from an Italian GD referral centre.
2  | PATIENTS AND METHODS
2.1 | Patients
In this study we recruited consecutive unrelated adult patients 
with type 1 GD confirmed by deficient GBA activity and defined 
progression in GD patients on stable ERT and may be a risk factor for long-term liver-
related complications.
K E Y W O R D S
controlled attenuation parameter, enzyme replacement therapy, glucocerebrosidase 
deficiency, liver stiffness, metabolic dysfunction-associated fatty liver disease
Lay summary
• Gaucher disease, a rare lysosomal storage disorder, is 
characterized by peculiar metabolic abnormalities and 
variable liver involvement, ranging from hepatomegaly 
to liver fibrosis/cirrhosis and hepatocellular carcinoma.
• The prevalence of and the factors associated with liver 
steatosis have not been systematically evaluated in pre-
vious cohorts of adult GD patients.
• In this study, adult patients with GD showed a high prev-
alence of liver steatosis that was significantly associated 
with a worse metabolic profile and liver fibrosis.
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mutations in the human GBA1 gene, monitored at the Regional 
Referral Centre for Lysosomal Storage Diseases, Division of Internal 
Medicine and Metabolism, Civil Hospital of Baggiovara, AOU of 
Modena, Italy, between 2015 and 2017.
A complete medical assessment, including evaluation of GD 
severity, anthropometric and metabolic parameters and VCTE 
(Fibroscan®) with CAP, was performed. Concurrent causes of liver 
steatosis were evaluated through medical history, imaging and bio-
chemical examinations. Dietary and lifestyle habits, including the 
amount of alcohol consumption, were also registered; significant 
alcohol consumption was defined as ≥20 g/d in women and ≥30 g/d 
in men.
The study was approved by the local ethics committee, and all 
participants gave written informed consent according to the Helsinki 
Declaration.
2.2 | Gaucher disease severity evaluation
Several GD parameters, including age at diagnosis, GBA1 genotype, 
history of splenectomy, dose and duration of ERT and GD severity, 
were assessed. GD severity at the time of evaluation was assessed 
using two validated scores: the Disease Severity scoring system 
for type 1 GD (GD1 DS3) 35 and the Severity Scoring Index (SSI).36 
Moderate-marked GD was defined as DS3 ≥ 3 or SSI > 10 respec-
tively. Liver and spleen volume were measured by magnetic reso-
nance imaging (MRI). Serum angiotensin converting enzyme (ACE) 
was determined by a standard enzyme activity assay.
2.3 | Anthropometric and metabolic parameters
Weight, height, body mass index (BMI), waist circumference and 
blood pressure were measured in all GD patients at the time of 
evaluation. Central obesity was defined as waist circumference 
>102 cm in men and >88 cm in women; high blood pressure was 
defined as systolic blood pressure ≥130 mm Hg and/or diastolic 
blood pressure ≥85 mm Hg and/or use of anti-hypertensive drugs. 
On the same day as the study visit, a fasting blood sample was 
obtained from each patient for measurements of glucose, insulin, 
glycated haemoglobin (HbA1c), lipid profile, alanine and aspartate 
aminotransferases (ALT and AST), gamma-glutamyltranspeptidase 
(GGT), ferritin, platelets count and albumin. Homeostatic model 
assessment of insulin resistance (HOMA-IR) was calculated using 
the following formula: [fasting insulin (mIU/L) x fasting glucose (mg/
dl)]/ 405. Patients with HOMA-IR ≥ 2 were considered as insulin-
resistant individuals. Altered glucose homeostasis was defined as a 
fasting glucose ≥110 mg/dL, hypertriglyceridemia as fasting triglyc-
erides levels ≥150 mg/dL and low HDL cholesterol as HDL choles-
terol levels <40 mg/dL in men and <50 mg/dL in women. MetS was 
diagnosed according to Adult Treatment Panel III (ATPIII) criteria.37
2.4 | Vibration-controlled transient elastography
All patients were submitted to VCTE (Fibroscan®) with CAP on the 
same day as the study visit. VCTE with CAP measurements were 
performed by using the M probe after at least 3 hours of fasting 
by a single experienced operator who had previously executed 
more than 500 examinations in patients with chronic liver disease 
(FN). Significant steatosis (grade S2 or higher) was defined as CAP 
values ≥ 250 dB/min.30
2.5 | Statistical analysis
Results were expressed as median [range] for numerical variables 
and frequencies (percentages) for categorical variables. Medians 
were compared by the Mann-Whitney U test and nominal variables 
by Pearson Chi-square and Fisher's exact test where appropriate. 
Spearman's rho was calculated for correlations between CAP values 
and other parameters. Because treatment with ERT may significantly 
affect GD progression over time, sensitivity analyses according to 
the length of ERT were conducted. A two-sided P < .05 was con-
sidered significant. Statistical analyses were performed using the 
statistical software package SPSS, version 17.0 for Windows (SPSS 
Inc, Illinois, USA).
3  | RESULTS
3.1 | General features of the overall study 
population
Twenty adult type 1 GD patients were enrolled in this study. The 
main clinical features of the overall study population are shown in 
Table 1. Men and women were equally represented; median age was 
48 [18-78] years. The majority of patients were carriers of at least 
one N370S GBA1 mutant variant and had mainly mild disease ac-
cording to DS3 and SSI. All but 2 patients were on ERT; 16 of these 
patients were on stable ERT for at least 24 months. Seven patients 
had a past history of splenectomy.
A significant proportion of patients had metabolic comorbidities: 
40% were overweight or obese; 50% had high blood pressure; 10% 
showed an altered glucose homeostasis (1 patient with impaired fast-
ing glucose and 1 patient with type 2 diabetes mellitus) and 15% were 
insulin-resistant according to HOMA-IR; 20% had full-blown MetS.
Median CAP values were 234 [165-358] dB/min; 8 patients 
(40%) showed CAP values ≥ 250 dB/min consistent with significant 
steatosis. Two patients, both men, reported a significant alcohol con-
sumption; 1 patient was a long-term responder to interferon-based 
therapy for post-transfusion chronic HCV infection; no other poten-
tial concurrent causes of liver steatosis were detected in the remain-
ing patients.
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3.2 | Factors associated with controlled 
attenuation parameter
The correlations between CAP values and the main demographic, 
biochemical, GD-related and metabolic factors are shown in 
Table 2. CAP values were not associated with age and gender 
(P = .226).
Several anthropometric and metabolic variables were significantly 
associated with CAP values. In particular, there were positive and 
significant correlations with all indices of increased adiposity, such 
as weight, BMI and waist circumference (Figure 1A,B). Consistently, 
overweight/obese patients showed significantly higher CAP values 
than patients with a normal BMI (269 [221-358] dB/min vs 211 [165-
269] dB/min, P = .004). Also patients with high blood pressure pre-
sented significantly higher CAP values than normotensive patients 
(262 [169-358] dB/min vs 216 [165-261] dB/min, P = .034); in par-
allel, we found a positive, although not statistically significant, asso-
ciation between diastolic blood pressure and CAP. Although we did 
not find significant associations between CAP values and glycaemia 
or HOMA-IR, patients with altered glucose homeostasis had signifi-
cantly higher CAP values than normoglycemic patients (321 [284-
358] dB/min vs 226 [165-295] dB/min, P = .032); similarly, CAP values 
were significantly higher in patients with insulin resistance according 
to HOMA-IR than in patients without (284 [251-295] dB/min vs 225 
[165-358] dB/min, P = .050). As shown in Figure 1C, CAP values were 
also positively and significantly associated with the number of factors 
of the MetS; as such, patients with the full-blown MetS presented 
significantly higher CAP values than those without (290 [251-358] 
dB/min vs 223 [165-276] dB/min, P = .008). Alcohol consumption 
was not significantly associated with CAP values; however, the 2 
patients with significant alcohol consumption showed significantly 
higher CAP values than their counterpart (327 [295-358] dB/min vs 
226 [165-284] dB/min, P = .023).
TA B L E  1   General characteristics of 20 adult patients with type 
1 Gaucher Disease
Demographic data
Age (years) 48 [18-78]
Male Gender 10 (50)
Gaucher disease-related data







Moderate-marked GD (DS3) 9 (45)
SSI 6 [1-16]
Moderate-marked GD (SSI) 5 (25)
Splenectomy 7 (35)
Liver volume (cc) 1450 [1106-2826]
Spleen volume (cc) 426 [203-975]
On ERT (imiglucerase) 18 (90)
Months of ERT 109 [0-275]
Dose of ERT (U/kg/month) 50 [0-120]
Cumulative dose of ERT (U/kg) 5145 [0-15860]
Anthropometric data
Weight (kg) 69 [52-104]
BMI (kg/m2) 24.3 [19.1-31.4]
BMI ≥ 25 kg/m2 8 (40)
Waist Circumference (cm) 90 [69-113]
Metabolic features
Central obesity 5 (25)
Altered glucose homeostasis 2 (10)
High blood pressure 10 (50)
Diastolic blood pressure (mm Hg) 78 [70-90]
Systolic blood pressure (mm Hg) 130 [100-150]
Hypertriglyceridemia 1 (5)
Low HDL cholesterol 9 (45)
N° of factors of metabolic syndrome 1 [0-4]
Metabolic syndrome (ATPIII) 4 (20)
Biochemical data
ACE (IU/L) 31 [5-191]
Ferritin (ng/ml) 93 [4-518]
Platelets (1000/mmc) 177 [88-453]
AST (IU/L) 21 [13-36]
ALT (IU/L) 21 [8-58]
GGT (IU/L) 34 [5-143]
Albumin (g/dl) 4.4 [3.5-5]
Glycaemia (mg/dl) 90 [72-110]
(Continues)
Demographic data
Insulinemia (mIU/L) 5.7 [2.1-21.3]
HOMA-IR (%) 1.3 [0.5-5.7]
HOMA-IR ≥ 2 3 (15)
HbA1c (%) 5.2 [4.2-5.9]
Triglyceridemia (mg/dL) 117 [25-275]
Total cholesterol (mg/dL) 193 [95-282]
HDL cholesterol (mg/dL) 44 [30-67]
LDL cholesterol (mg/dL) 125 [53-208]
Transient elastography data
CAP (dB/min) 234 [165-358]
Significant steatosis 8 (40)
Liver stiffness (kPa) 4.8 [3-11.3]
Other data
Alcohol consumption (g/day) 0 [0-50]
Significant alcohol consumption 2 (10)
TA B L E  1   (Continued)
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Concerning GD-related variables, we did not find any correla-
tions between CAP values and GD severity as assessed either by 
scores (DS3 and SSI) or biomarkers (ACE, HDL cholesterol, ferritin, 
platelets). GBA1 genotype (P = .217), splenectomy (P = .721) and 
dose and duration of ERT were not associated with CAP values. 
Patients on stable ERT for at least 24 months did not show a sig-
nificant difference in CAP values with respect to patients who have 
received ERT for < 24 months (P = .156).
CAP values were not significantly associated with liver volume, 
liver enzymes and liver stiffness in the overall study population.
3.3 | Factors associated with significant steatosis
Table 3 shows a comparison of the main features of GD patients 
with and without significant steatosis as evaluated by CAP. The fac-
tors associated with significant steatosis were fully consistent with 
the results obtained for CAP values. In particular, GD patients with 
significant steatosis clearly showed a worse metabolic profile than 





Age (years) 0.176 0.457
Gaucher Disease-related data
Age at diagnosis (years) 0.002 0.992
DS3 -0.140 0.557
SSI 0.207 0.382
Liver volume (cc) 0.154 0.516
Spleen volume (cc) -0.137 0.655
Months of ERT 0.276 0.239
Dose of ERT (U/kg/month) -0.406 0.076
Cumulative dose of ERT (U/kg) 0.164 0.490
Anthropometric data
Weight (kg) 0.609 0.004
BMI (kg/m2) 0.671 0.001
Waist Circumference (cm) 0.575 0.008
Metabolic features
Diastolic blood pressure (mm Hg) 0.436 0.055
Systolic blood pressure (mm Hg) 0.185 0.436
N° of factors of metabolic syndrome 0.470 0.037
Biochemical data
ACE (IU/L) -0.050 0.835
Ferritin (ng/mL) 0.243 0.302
Platelets (1000/mmc) 0.192 0.416
AST (IU/L) 0.422 0.064
ALT (IU/L) 0.377 0.102
GGT (IU/L) 0.293 0.210
Albumin (g/dl) -0.018 0.939
Glycaemia (mg/dl) 0.347 0.134
Insulinemia (mIU/L) 0.043 0.858
HOMA-IR (%) 0.159 0.502
HbA1c (%) 0.262 0.265
Triglyceridemia (mg/dl) 0.285 0.224
Total cholesterol (mg/dl) -0.260 0.268
HDL cholesterol (mg/dl) -0.031 0.897
LDL cholesterol (mg/dl) -0.190 0.423
Transient elastography data
Liver stiffness (kPa) 0.224 0.342
Other data
Alcohol consumption (g/day) 0.352 0.127
F I G U R E  1   Correlations between controlled attenuation 
parameter and metabolic risk factors in the overall cohort. 
Correlations between controlled attenuation parameter and body 
mass index (A), waist circumference (B) and number of factors of 
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TA B L E  3   Comparison between type 1 Gaucher Disease patients with and without significant steatosis
Patients without significant 
steatosis (n = 12)
Patients with significant steatosis 
(n = 8) P*
Demographic data
Age (years) 43 [16-78] 52 [37-76] 0.189
Male Gender 6 (50) 4 (50) 1.000
Gaucher Disease-related data
Age at diagnosis (years) 27 [2-62] 29 [4-51] 1.000
Genotype 0.067
N370S/N370S 6 (50) 2 (25)
N370S/Other 6 (50) 3 (38)
Other/Other 0 (0) 3 (38)
Gaucher Disease severity
DS3 1.4 [0-6.3] 2.5 [0-6.7] 0.726
Moderate-marked GD (DS3) 5 (42) 4 (50) 1.000
SSI 4.5 [1-13] 7.5 [4-16] 0.096
Moderate-marked GD (SSI) 2 (17) 3 (38) 0.347
Splenectomy 3 (25) 4 (50) 0.356
Liver volume (cc) 1410 [1108-2826] 1494 [1106-2300] 0.938
Spleen volume (cc) 380 [203-975] 513 [216-723] 0.877
On ERT (imiglucerase) 11 (92) 7 (88) 1.000
Months of ERT 75 [0-244] 130 [9-275] 0.203
Dose of ERT (U/kg/month) 58 [0-120] 45 [30-120] 0.129
Cumulative dose of ERT (U/kg) 4970 [0-12 200] 5375 [1080-15 860] 0.487
Anthropometric data
Weight (kg) 64 [52-82] 77 [58-104] 0.023
BMI (kg/m2) 23.2 [19.1-26] 27.1 [21.1-31.4] 0.007
BMI ≥ 25 kg/m2 2 (17) 6 (75) 0.009
Waist Circumference (cm) 85 [69-98] 95 [78-113] 0.034
Metabolic features
Central obesity 0 (0) 5 (63) 0.004
Altered glucose homeostasis 0 (0) 2 (25) 0.147
High blood pressure 3 (25) 7 (88) 0.020
Diastolic blood pressure (mmHg) 73 [70-90] 88 [75-90] 0.010
Systolic blood pressure (mmHg) 128 [100-150] 138 [115-140] 0.159
Hypertriglyceridemia 0 (0) 1 (13) 0.400
Low HDL cholesterol 5 (42) 4 (50) 1.000
N° of factors of metabolic syndrome 1 [0-2] 3 [0-4] 0.058
Metabolic syndrome (ATPIII) 0 (0) 4 (50) 0.014
Biochemical data
ACE (IU/L) 35 [8-191] 25 [5-113] 0.643
Ferritin (ng/ml) 93 [4-342] 93 [29-518] 0.817
Platelets (1000/mmc) 160 [88-453] 198 [121-374] 0.440
AST (IU/L) 19 [13-31] 22 [17-36] 0.202
ALT (IU/L) 16 [8-46] 22 [19-58] 0.053
GGT (IU/L) 24 [5-143] 36 [13-88] 0.315
Albumin (g/dl) 4.4 [3.6-5] 4.3 [3.5-4.5] 0.258
(Continues)
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GD patients without significant steatosis. Indeed, patients with sig-
nificant steatosis presented more frequently overweight/obesity, 
high blood pressure, insulin resistance and MetS, and had higher 
values of weight, BMI, waist circumference, diastolic blood pressure 
and glycaemia than their counterpart without significant steatosis. 
Moreover, there was a non-statistically significant overrepresenta-
tion of patients with significant alcohol consumption among those 
with significant steatosis. GD-related variables and ERT dose and du-
ration were not significantly different between GD patients with and 
without significant steatosis. The prevalence of significant steatosis in 
GD patients on stable ERT for at least 24 months did not significantly 
differ from those who received ERT for <24 months (44% vs 25%, 
P = .494). There were no significant differences between GD patients 
with and without liver steatosis with respect to liver volume, liver en-
zymes and liver stiffness in the overall study population.
3.4 | Sensitivity analyses according to the 
length of ERT
Analyses were repeated among the 16 patients who were on stable 
ERT for at least 24 months. BMI (rho = 0.624, P = .010), waist cir-
cumference (rho = 0.531, P = .034) and the number of factors of the 
MetS (rho = 0.656, P = .006), as well as overweight/obesity (P = .049), 
insulin resistance (P = .029), high blood pressure (P = .006) and MetS 
(P = .009), were all confirmed as factors significantly and positively as-
sociated with CAP or significant steatosis in this subgroup of patients. 
Of note, CAP was also significantly associated with liver stiffness (rho 
0.559, P = .024) (Figure 2); consistently, GD patients with significant 
steatosis showed higher liver stiffness values than those without sig-
nificant steatosis (6.8 [3-11.3] kPa vs 4.3 [3-5.1] kPa, P = .026).
4  | DISCUSSION
In this study, we assessed the prevalence of significant liver steato-
sis evaluated by CAP in a cohort of Italian adult patients with type 
1 GD. Next, we evaluated which factors among metabolic features, 
GD-related variables and treatment with ERT were associated with 
CAP values and significant liver steatosis. Finally, we investigated 
if liver steatosis by CAP was associated with liver fibrosis by VCTE. 
We showed that significant liver steatosis was highly prevalent in 
our cohort of adult type 1 GD patients, affecting 40% of individu-
als. Features of the MetS, including indices of adiposity, high blood 
pressure and insulin resistance, as well as significant alcohol con-
sumption, were the main factors associated with CAP values and 
significant liver steatosis. However, we did not find any significant 
association between liver steatosis by CAP, GD-related variables 
and treatment with ERT. We also demonstrated that liver steato-
sis by CAP was directly associated with liver stiffness assessed by 
VCTE, a parameter primarily related to the degree of liver fibrosis, 
in the subgroup of type 1 GD patients on stable ERT for at least 
2 years.
There are several theoretical assumptions that support an as-
sociation between GD and liver steatosis. Firstly, besides being a 
terminal catabolic station, the lysosome acts as a metabolic signal-
ling hub that is involved in nutrient sensing and energy homeosta-
sis.12 Increasing data have shown that lysosomal dysfunction and 
subsequent metabolic derangements are associated with several 
pathological conditions in humans, including lysosomal storage 
diseases, GD being the prototype of these inherited metabolic dis-
orders, as well as obesity, MetS and liver steatosis.12,38 Secondly, 
alterations in the balance between compounds of the sphingomy-
elin-ceramide-glycosphingolipid pathways play a key role in some 
Patients without significant 
steatosis (n = 12)
Patients with significant steatosis 
(n = 8) P*
Glycaemia (mg/dl) 87 [78-93] 94 [72-110] 0.027
Insulinemia (mIU/L) 5.3 [2.7-8.8] 6.2 [2.1-21.3] 0.563
HOMA-IR (%) 1.1 [0.5-2] 1.6 [0.5-5.7] 0.280
HOMA-IR ≥ 2 0 (0) 3 (38) 0.049
HbA1c (%) 5.2 [4.2-5.9] 5.6 [4.9-5.9] 0.093
Triglyceridemia (mg/dl) 113 [25-137] 119 [70-275] 0.354
Total cholesterol (mg/dl) 196 [95-240] 173 [127-282] 0.247
HDL cholesterol (mg/dl) 44 [30-64] 45 [30-67] 0.969
LDL cholesterol (mg/dl) 132 [53-191] 105 [72-208] 0.375
Transient elastography data
CAP (dB/min) 211 [165-245] 273 [251-358] <0.001
Liver stiffness (kPa) 4.4 [3-8.1] 6.7 [3-11.3] 0.132
Other data
Alcohol consumption (g/day) 0 [0-25] 0 [0-50] 0.392
Significant alcohol consumption 0 (0) 2 (25) 0.068
*Pearson Chi-square, Fisher's exact test or Mann-Whitney U test, where appropriate. 
TA B L E  3   (Continued)
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metabolic abnormalities, such as insulin resistance, that have been 
described in GD patients and in subjects with liver steatosis.13,39 
Moreover, GD-specific treatment, in particular ERT, has been as-
sociated with significant weight gain in adults.8,15 With regard to 
this aspect, it has been shown that GD is characterized by an in-
creased resting energy expenditure, which is significantly reduced 
by ERT; however, if the energy intake remains unchanged, the de-
crease in hypermetabolism during ERT determines an increase in 
weight and in fat mass.8,40 Finally, unhealthy lifestyles, character-
ized by overnutrition, unbalanced diet, alcohol misuse and seden-
tariness, are likely overlooked in the current treated and ageing 
population of GD patients.8 Despite these premises, the presence 
of liver steatosis has rarely been evaluated in previously published 
cohorts of GD patients. Webb et al reported a prevalence of liver 
steatosis evaluated by abdominal ultrasound of 37% among 42 
type 1 GD patients from Israel.41 A very recent study from Poland 
found that liver steatosis defined by CAP values > 250 dB/m was 
present in 22% of a mixed cohort of 59 adult and paediatric, type 
1 and type 3 GD patients.42 The prevalence of liver steatosis in 
our study (40%) is similar to that reported by Webb,41 but signifi-
cantly higher than that found in the Polish cohort.42 Since ageing 
is a strong determinant of the development of liver steatosis, the 
difference in the mean or median age between the three GD co-
horts may partly account for this discrepancy. Indeed, the mean 
age of the Israeli cohort (49.2 years) was the same to that of our 
GD population (49.2 years),41 whereas the median age in Polish GD 
patients was significantly lower (35 years).42 These data collec-
tively suggest that the prevalence of liver steatosis in GD patients 
is remarkable and even seems to be higher than that reported in 
the general population, which ranges from 14% in Africa to 31%-
32% in South America and the Middle East.20
The high rates of metabolic abnormalities described in treated 
GD patients may easily justify the above-mentioned finding.8 It is 
well known that GD is strongly associated with peripheral insulin 
resistance 10,39; moreover, many ageing GD patients develop type 2 
diabetes in parallel with increasing weight and occurrence of over-
weight/obesity and MetS.15 However, the factors associated with 
liver steatosis in GD patients have not been extensively analysed so 
far. Lipinski et al found a significant and independent association be-
tween CAP values and BMI in their cohort of Polish GD patients, but 
the potential associations with other relevant metabolic variables 
were not explored in detail.42 Here, we have comprehensively eval-
uated the factors associated with liver steatosis in GD patients for 
the first time. As for the general population,29 we showed that all the 
major components of the MetS, including visceral adiposity, altered 
glucose homeostasis and high blood pressure, were associated with 
CAP values and/or the presence of significant steatosis. On the con-
trary, we did not find any association between CAP/liver steatosis 
and GD-related variables or ERT. Moreover, alcohol misuse was also 
associated with steatosis, suggesting that unhealthy lifestyle may 
have a major contribution in metabolic disturbances found in our GD 
patients. Future studies are needed to carefully investigate dietary 
patterns and physical activity in adult GD subjects.
One may question if CAP actually reflects the accumulation of 
triglycerides in hepatocytes, that is liver steatosis, in GD patients, 
or rather represents the storage of other lipid species characteristic 
of GD, such as glycosphingolipids in liver macrophages and Kupffer 
cells. Since the factors we found to be associated with CAP in our GD 
cohort are the same factors identified in cohorts of biopsy-proven 
patients with liver steatosis of different aetiologies,30 we may safely 
infer that CAP values are representative of liver steatosis also in GD 
patients.
F I G U R E  2   Correlation between 
controlled attenuation parameter and liver 
stiffness in the subgroup of patients on 
stable enzyme replacement therapy for at 
least 24 months
rho 0.559, p = 0.024
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A previous work of our group among that same cohort of GD 
patients showed that several components of the MetS, including 
BMI and arterial blood pressure, were significantly and positively 
associated with liver stiffness in the subgroup of subjects on sta-
ble long-term ERT.5 In the current study, we were able to demon-
strate that liver steatosis, mainly attributable to MAFLD, is a major 
driver of liver fibrosis in GD patients on ERT. MAFLD is the most 
common chronic liver disease and is the most rapidly growing cause 
of cirrhosis, end-stage liver disease and HCC.19,22 As a consequence, 
MAFLD-related fibrosis may be a neglected contributing factor for 
the high incidence of HCC reported in GD patients.6,43
Some limitations of the current study have to be acknowledged. 
Firstly, the cohort is relatively small, thus, our findings need to be rep-
licated in larger, multicentre studies. Secondly, liver biopsy or mag-
netic resonance spectroscopy that are the gold-standard for liver fat 
detection and quantification were not performed. However, it should 
be emphasized that this is the first study in which, besides undergoing 
a comprehensive metabolic assessment, GD patients were also sys-
tematically evaluated for the presence of liver steatosis and fibrosis.
In conclusion, significant liver steatosis as evaluated by CAP is 
highly prevalent in adult type 1 GD patients, is associated with the 
features of the MetS and unhealthy lifestyle and correlates with liver 
fibrosis in ERT-treated subjects. Since MAFLD is a strong risk factor 
for long-term liver-related complications, including HCC, and car-
diovascular morbidity and mortality, it seems appropriate to include 
the evaluation of liver steatosis in the overall assessment of all adult 
GD patients. Metabolic complications, including MAFLD, should be 
regularly monitored, and lifestyle advices and interventions promot-
ing healthy dietary patterns, avoidance of alcohol misuse and regu-
lar physical activity should be encouraged in all GD patients.
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